Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

Tytuł:
Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial
Autorzy:
Akinori Hara
Miho Shimizu
Erika Hamaguchi
Hirokazu Kakuda
Kenzo Ikeda
Toshiya Okumura
Kiyoki Kitagawa
Yoshitaka Koshino
Motoo Kobayashi
Kazuya Takasawa
Yukimasa Hisada
Tadashi Toyama
Yasunori Iwata
Norihiko Sakai
Takashi Wada
Temat:
albuminuria
CCR2
diabetes
kidney
MCP‐1
propagermanium
Diseases of the endocrine glands. Clinical endocrinology
RC648-665
Źródło:
Endocrinology, Diabetes & Metabolism, Vol 3, Iss 3, Pp n/a-n/a (2020)
Wydawca:
Wiley, 2020.
Rok publikacji:
2020
Kolekcja:
LCC:Diseases of the endocrine glands. Clinical endocrinology
Typ dokumentu:
article
Opis pliku:
electronic resource
Język:
English
ISSN:
2398-9238
Relacje:
https://doaj.org/toc/2398-9238
DOI:
10.1002/edm2.159
Dostęp URL:
https://doaj.org/article/e80ee15214754680a4bcc0ec00aa9d86  Link otwiera się w nowym oknie
Numer akcesji:
edsdoj.80ee15214754680a4bcc0ec00aa9d86
Czasopismo naukowe
Summary Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods We recruited patients from nine medical institutions in Japan for this randomized, open‐label, parallel two‐arm pilot trial. Inclusion criteria were diagnosis of type 2 diabetes, age 30‐75 years, dipstick proteinuria of ≥1+ or urinary albumin‐to‐creatinine ratio (UACR) of ≥30 mg/g and estimated glomerular filtration rate of ≥30 mL/min/1.73 m2. Patients were randomly assigned (1:2) using a minimization algorithm to either continuing usual care or concomitant administration of 30 mg PG per day for 12 months. The primary outcome was the change in UACR from baseline to 12 months. We also collected safety information for all patients who received at least one dose of PG. Results We enrolled 29 patients, 10 were assigned to continue usual care and 19 to receive PG. Changes in UACR by PG in addition to the usual care were 25.0% (95% CI −20.4%, 96.5%, P = .33). No severe adverse events or renal events were observed during the study. Conclusion Although the treatment with PG was generally well tolerated, the dosage of 30 mg/d for 12 months did not reduce albuminuria when used in addition to usual care in patients with type 2 diabetes and nephropathy. Efficacy of PG should be verified in future definitive trials.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies